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In patients with glomerulonephritis widespread crescents are associated with a poor prognosis. 
Crescent formation appears to depend on the migration of mononuclear cells into Bowman's 
space, and therefore the interaction between leukocytes and glomerular endothelium may be a 
critical event in the genesis of crescents. We performed the present study to determine the effects 
of mouse monoclonal antibodies  to the adhesion molecules intercellular adhesion molecule 1 
(ICAM-1) and lymphocyte function-associated antigen 1 (LFA-1) in a model of crescentic glo- 
merulonephritis in Wistar-Kyoto rats, induced by immunization with bovine glomerular basement 
membrane (GBM). By 10-14 d after immunization, the rats had developed circulating anti-GBM 
antibodies, reactive with the oL3 chain of type IV collagen (the Goodpasture antigen), accompanied 
by proteinuria,  accumulation  of rat immunoglobulin (Ig)G in the GBM,  increased expression 
of ICAM-1 by glomerular endothelial cells, infiltration of glomerular tufts with LFA-1  + T cells 
and monocyte/macrophages, and early crescents. At 5 wk all rats had diffuse fibrocellular crescents, 
glomerular sclerosis, and tubulointerstitial  damage. All rats developed severe renal insufficiency 
and died by 5 or 6 wk. The administration  of monoclonal antibodies to rat ICAM-1 and LFA-1 
markedly decreased the severity of the renal disease. In a group of rats injected three times a 
week with the monoclonal antibodies,  from 2 d before immunization with GBM to day 14, 
glomerular abnormalities and proteinuria were virtually absent at day 14; even  at 5 wk glomerular 
disease was quite mild, with only slight crescent formation and with only a mild decrease in 
renal function. When treatment was continued until 5 wk, the beneficial effects were even more 
marked, with virtual absence of crescents and with preservation of normal renal function. In 
a group of rats in which treatment was initiated on day 14, shortly after the appearance  of glomerular 
abnormalities, progression of the disease  was appreciably  retarded, and the decrease  in renal function 
was inhibited.  The kidneys of rats treated from days -2 to 14 with antibodies to ICAM-1 and 
LFA-1 showed bright linear staining for rat IgG along the GBM, which did not differ in intensity 
from that seen in untreated rats. Furthermore, the titers of anti-GBM  antibodies  at 2 wk in 
treated rats were not lower than that seen in most of the untreated rats. There was, however, 
moderate reduction of anti-GBM  antibodies  at 5 wk in the treated rats.  In addition,  in rats 
in which treatment was started after onset of the disease, the titers of anti-GBM antibodies did 
not decrease, although the progression of disease was inhibited.  We conclude that the preventive 
or therapeutic effects of antibodies to ICAM-1 and LFA-1 in rat anti-GBM glomerulonephritis 
probably resulted mainly from interference with interaction  between leukocytes and activated 
glomerular endothelium, although reduction in the autoimmune response may have contributed 
to the beneficial effects. The results raise the possibility that similar treatment might be used 
to limit the progression  of glomerular damage in human crescentic glomerulonephritis. 
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n patients with glomerulonephritis the formation of cres- 
cents is usually associated with an ominous prognosis (1). 
Crescents are thought to be induced by an influx of circulating 
monocytes/macrophages (2--4) and plasma proteins (5, 6) into 
Bowman's space, mainly through gaps in the glomerular base- 
ment membrane (GBM)  1 (7, 8). Gaps are apparently induced 
by proteolytic enzymes released  by  leukocytes that  have 
migrated across the endothelium (9). Thus, the interaction 
between endothelium and leukocytes may be a critical event 
in the formation of crescents. 
The migration of leukocytes through inflamed blood vessds 
requires  the adhesion of leukocytes to the endothelium, a 
phenomenon mediated by endothelial and leukocyte surface 
molecules functioning as receptors  and ligands (10). One of 
the most important interactions is between intercellular adhe- 
sion molecule 1 (ICAM-1) and LFA-1. ICAM-I (CD54) is 
a member of the Ig superfamily, which is expressed on a va- 
riety of hematopoietic cells, as well as on endothelial cells, 
fibroblasts, and certain epithelial cells. LFA-1 (CDlla/CD18) 
is a leukocyte cell surface glycoprotein widely expressed  on 
cells of the hematopoietic lineage (11). 
The present report describes  the effect of mAbs against 
rat ICAM-1 and LFA-1 in Wistar-Kyoto rats with a lethal 
autoimmune anti-GBM nephritis (12). This disease is charac- 
terized by development of antibodies reactive with the Good- 
pasture's antigen (13), linear deposition of rat IgG in the GBM 
(12), infiltration of glomeruli by T lymphocytes and mono- 
cyte/macrophages, widespread crescent formation, and glo- 
merular sclerosis. We found that injections of anti-ICAM-1 
and LFA-1 antibodies prevented the formation of crescents, 
markedly reduced the severity of other glomerular and tu- 
blointerstitial lesions,  and  prolonged  the  survival  of the 
animals. 
Materials  and Methods 
Animals.  Wistar-Kyoto  rats weighing 150-180 g were purchased 
from Charles River Breeding  Laboratories  (Wilmington, MA), and 
allowed free access to food and water. 
Antigen Preparation and Rat Immunization.  GBM was isolated 
from fresh bovine kidneys  using a differential sieving method (14). 
GBM was sonicated, digested with collagenase (type VII; Sigma 
Chemical Co., St. Louis, MO) at 37~  for 16 h in 0.05 M Hepes 
buffer (pH 7.4) with 0.01 M CaCh, and centrifuged at 14,500 g 
for 30 min. The pellets were resuspended in 0.1 M citrate buffer, 
pH 3.0. The rats were immunized (on day 0) by a single subcuta- 
neous injection of 50 mg (wet weight) of the GBM homogenate 
emulsified with an equal volume of CFA (Sigma Chemical Co.), 
and an injection at a different subcutaneous  site with 5 x  109 cells 
of pertussis vaccine (Michigan Public Health, Lansing, MI). 
mAbs.  A mouse IgG1 anti-rat ICAM-1 mAb (1A29) and a 
mouse IgG2 anti-rat LFA-1 mAb (WT.1) were generated  and charac- 
terized as previously  described  (15, 16). An IgG1 mouse anti-diethyl 
thiamine pentaacetic acid (DTPA) antibody and an IgG2a mouse 
1 Abbreviations used in thispaper: DTPA, diethyl  thiamine  pentaacetic acid; 
GBM, glomerular  basement membrane; ICAM-1, intercellular  adhesion 
molecule 1. 
anti-human CD44 antibody, which did not react with rat tissues, 
were used as isotype controls. The ascitic supernatants  were purified 
on protein A-Sepharose CL-4B columns. 
Histologic Methods.  Samples  of renal tissue were obtained at 7, 
10-14, and 35 d, and 10-20 wk after immunization. Tissue was 
fixed in 10% buffered  formalin, and embedded  in paraffin.  Sections 
of 4/zm were stained with hematoxylin-eosin (H&E) and by the 
periodic acid-Schiff  method. The number of nuclei was counted 
in cross-sections of 10 glomeruli randomly selected  in a histologic 
section from six rats in each group. Crescents were counted in 50 
glomeruli randomly selected  in sections  from six rats of  each group. 
Crescents were roughly divided  into three groups: (a) circumferen- 
tial; (b) those involving about one-half of the glomerulus; and (c) 
those involving a quarter or less of the glomerulus. 
Immunofluorescence Methods.  Fluorescein-conjugated  (FITC)-IgG 
fractions of goat or rabbit antisera to rat IgG, C3, and fibrinogen 
were purchased from  Cappel Laboratories (Cochranville, PA). 
ICAM-1 and LFA-1 were revealed  by successive  incubations  of tissue 
sections with normal goat serum, relevant  mouse  mAbs, and affinity- 
purified FITC-goat anti-mouse IgG (Cappel Laboratories)  that had 
been extensively absorbed with rat serum. As controls, we used 
the irrelevant  isotype-matched  antibodies against DTPA and human 
CD44. The immunofluorescence  methods, including controls, were 
performed as previously described (17). The intensity of staining 
for rat IgG along the GBM was semiquantitatively graded on a 
scale from 0 to + + + (0, absent; +, minimal; + +, moderate; + + +, 
marked). The interpretations were performed without knowledge 
of the group in at least 15-20 glomeruli from three sections from 
each group. When extensive  formation of  crescents and glomerulo- 
sclerosis were present (groups II and III) evaluation of glomerular 
staining was based on residual, relatively  undamaged,  capillary  loops. 
The sections were mounted in a medium containing p-phenyl- 
lenediamine to reduce fading (18) and examined  with a Nikon mi- 
croscope equipped with epifluorescence  optics and appropriate filters. 
Immunoperoxidase Methods.  Mouse  IgG bound to renal tissues 
of  rats injected with the mAbs to ICAM-1 and LFA-1 was detected 
by an immunoperoxidase technique using biotin-labeled affinity- 
purified horse anti-mouse IgG (Vector  Labs, Inc., Burlingame,  CA), 
previously  absorbed with rat serum, and avidin-biotinylated  horse- 
radish peroxidase complexes (Vector Labs, Inc.). The phenotype 
of inflammatory cells was determined by the use of mouse mAbs 
to rat T lymphocytes  (W3/13) (Accurate  Chem. & Sci. Corp., West- 
bury, NY) and to rat monocyte/macrophages  (ED1) kindly provided 
by Dr. C. D. Dijkstra (19). Sections of frozen kidney were cut at 
4 #m in a cryostat, fixed in acetone for 10 min at room tempera- 
ture, air dried, and incubated with the primary mouse mAb fol- 
lowed by biotin-labeled afffinity-purified  horse anti-mouse  IgG 
(Vector Labs, Inc.) (dilution, 1:200; 30 min), and avidin-biotinylated 
horseradish peroxidase  complexes  (Vector  Labs, Inc.) (dilution, 1:100; 
45 min). The sections were then treated for 1-5 min with 0.04% 
AEC (Sigma Chemical Co.) in 0.03%  H202 in 0.1 M acetate 
buffer, pH 5.0, rinsed with distilled  water, and counterstained  with 
hematoxylin. Controls for the immunoperoxidase  studies  were per- 
formed as previously described (20). The number of positive cells 
was counted in 10 randomly selected  glomerular cross-sections  ob- 
tained from six rats of each group. The intensity of interstitial 
mononudear cell infiltration was estimated by counting T lym- 
phocytes and monocyte/macrophages  in five  randomly selected  renal 
cortical areas of 0.25 mm  2, in sections from six rats in each group, 
using a 19-mm diameter micrometer disk (Olympus Corp., Lake 
Success, NY) inserted into an ocular lens of the microscope (21). 
Urinary Output and Protein Excretion.  16-h  urinary samples were 
collected in metabolic  cages and their volumes  were measured. Uri- 
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method. 
Serum Creatinine.  Serum creatinine was measured by a quan- 
titative colorimetric assay (Sigma Chemical Co.). 
Serum Antibody to the or3 Chain of Type IV Collagen.  Serum 
samples from individual rats in groups I, II, IV, and VI were tested 
by an ELISA kit (Biocarb Diagnostics; SciMedx Corp., DenviUe, 
NJ). In group II, 16, of 20 randomly selected rats were tested at 
2 wk, and seven at 5 wk. In group IV, all rats were tested at 2 wk, 
and seven of eight at 5 wk. In group VI, all rats were tested at 
5 wk. Microtiter strips coated with the r  chain of type IV col- 
lagen (the Goodpasture antigen [22]) were incubated with a 1:25 
dilution of the rat sera as well as three reference-positive human 
sera,  which had been arbitrarily defined by the manufacturer to 
contain 1,000,  100, and 10 ELISA units, respectively. In addition, 
normal human serum was analyzed. All samples were tested in dupli- 
cate. After a 1-h incubation and three washes, specific binding of 
rat or human IgG was detected using either an alkaline phospha- 
tase-conjugated rabbit antibody to rat IgG or an alkaline phospha- 
tase-conjugated antibody to human  IgG. Finally, the substrate 
p-nitrophenyl-phosphate was added, and absorbances were read at 
405 nm in a ED310  (BioTek Instruments, Winooski, VT) ELISA 
Table  1.  Experimental  Design 
auto reader at time 0 and at 60 min for each well. The net absor- 
bance change was determined for each well by subtracting time 
0 from 60 min. The optical densities of the three reference sera 
were plotted against the defined ELISA units on a Log-linear scale 
in order to construct a standard curve. The value for each unknown 
rat serum was then determined from the standard curve. 
PBL.  Samples of peripheral blood were collected in heparinized 
tubes from normal rats, and from rats at 2 and 5 wk after immuni- 
zation. Total leukocytes were counted using a hemocytometer (Fisher 
Scientific Co., Pittsburgh, PA). Differential leukocyte counts based 
on 100 cells were performed on blood smears stained with Wright- 
Giemsa (Sigma Chemical Co.). 
Statistical Analysis.  The data are expressed as means •  SD. An 
unpaired t test was used for comparison. 
Experimental  Design.  The  experimental design is  shown  in 
Table 1. 
Results 
The main results are summarized in Table 2; further de- 
tails are given below. 
Group  No.  of rats  Immunization (day 0) 
I  6/6  None/CFA 
II  20  GBM  +  CFA 
III  6  GBM  +  CFA 
IV  8  GBM  +  CFA 
V  6  GBM  +  CFA 
VI  6  GBM  +  CFA 
mAbs 
None 
None 
Anti-DTPA  +  anti-human CD44 
Anti-rat ICAM-I  +  anti-rat LFA-1 
Anti-rat ICAM-1  +  anti-rat LFA-I 
Anti-rat ICAM-1  +  anti-rat LFA-1 
Antibody injections* (d) 
-  2  0  7  14  21  28  35 
II  I  I  I  I  I 
* 0.5 mg i.v. and 0.5 mg i.p. three times a week. 
Table  2.  Morphological, Immunohistochemical, and Serological Findings 
Group 
I  II  III  IV  V  VI 
Glomerular cellularity at 2  wk  49  •  1 
Crescent formation at 5 wk 
Circumferential (%)  0  •  0 
1/2  glomerulus (%)  0  •  0 
1/4 glomerulus (%)  0  •  0 
Interstitial cellularity at 5 wk 
Monocyte/macrophages  2  •  0 
T  lymphocytes  2  •  1 
Rat IgG in GBM at 2 wk  0 
Creatinine at 5 wk  (mg/dl)  0.60  •  0.05 
116•  113  •  49•  49•  116• 
68  •  11  64  •  18  1•  0  •  0*  0•  0* 
24•  24  •  10  2•  0  •  0*  3• 
8•  8•  9•  7•  28• 
170  •  31  160  •  18  15  +  3*  ND  ND 
61  •  31  57  •  12  35  •  25*  ND  ND 
+++  +++  +++  +++  +++ 
1.60  _+  0.48  1.61  +  0.59  0.87  •  0.12"  0.75  +  0.19"  0.89  •  0.17" 
* Significant difference when compared with groups II or III (p <0.01). 
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Kidney tissue obtained at 10--14 d and 5 wk showed no histo- 
logic or immunohistochemical abnormalities. ICAM-1 was 
weakly expressed by the endothelial cells of large vessds, peri- 
tubular capillaries,  and glomeruli. Tubule calls did not stain 
for ICAM-1. Rare LFA-1 + cells were present in some large 
blood vessels. The urinary protein excretion was normal (20--40 
mg/d). The PBL count was 5,190  _+  1,114/ram  3. Serum cre- 
atinine levels were normal and no circulating antibodies to 
the or3 chain of type IV collagen were found. 
Group II. Rats Immunized with Bovine GBM in CFA.  7 d 
after immunization, renal specimens revealed no abnormal 
histologic or immunohistochemical findings. There was no 
abnormal proteinuria. 
10-14 d after immunization, all rats had increased urinary 
protein excretion (Fig.  1), linear deposition of rat IgG in the 
GBM (+ + +) and in tubular basement membranes, and mild 
glomerular abnormalities characterized by irregular hyper- 
cellularity of tufts, adhesions, and early crescents (Fig. 2 a). 
Minimal deposition of C3 in the GBM was also observed. 
Mononuclear cells expressing markers of T lymphocytes and 
monocyte/macrophages (Fig. 2 b) and LFA-1 (Fig. 2 c) were 
found in glomerular capillaries,  in Bowman's space, in areas 
of glomerulo-capsular adhesions, and in nascent crescents. 
Neutrophils were not present. The expression of ICAM-1 
in the glomerular endothelial ceils was greater than in normal 
rats or in immunized rats at day 7 (Fig.  2, d and e). Weak 
staining for ICAM-1 was also found in the brush border of 
proximal tubules. The sera of 16 rats in group II were tested 
for the antibodies to the 0<3 chain of type IV collagen, and 
all the sera contained antibodies (Fig.  3).  In 15 of the rats 
the titers were relatively low (36.3  _  21.8 U); however, one 
rat had a very high titer (350 U). The renal lesions of this 
rat did not differ from those of the others. The average PBL 
count was 7,513  _  835/mm  3, and the differential count re- 
vealed 27  __.  5%  polymorphonuclear cells and 73  _  5% 
mononudear cells. 
5 wk after immunization, circumferential fibrocellular or 
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Figure 1.  Urinary protein excretion  in treated  and untreated  rats. 
fibrotic crescents with partial or complete sclerosis of tufts 
were observed in most glomeruli (Fig. 4). Linear GBM staining 
for IgG (+ + + ) was seen in nonsderotic portions of glomeruli. 
The crescents were stained intensely by antifibrinogen anti- 
bodies (Fig.  4,  inset). There was irregular tubular atrophy 
and focal interstitial fibrosis. Markedly increased expression 
of ICAM-1 was detected in the endothelium and in the mesan- 
gial matrix of glomeruli (Fig.  5 a), and in the brush border 
of the proximal tubule cells. LFA-1-positive  T lymphocytes 
and monocyte/macrophages were present in the tufts, cres- 
cents, in Bowmaffs capsule,  and in the interstitium, espe- 
cially around glomeruli (Fig.  5 c-J).  All rats tested had cir- 
culating antibodies to the or3 chain of type IV collagen (Fig. 
3), increased urinary protein and serum creatinine, and de- 
creased urinary output (Fig.  1). The rats appeared sick, de- 
veloped ascites, and died in uremia 5-6 wk after immunization. 
Group III. Rats Immunized with Bovine GBM in CFA and 
Injected with Irrelevant anti-DTPA and Human  CD44 mAbs. 
The histological, immunohistochemical, functional, and sero- 
logical findings were similar to  those observed in rats of 
group II. 
Group IV. Rats Immunized  with Bovine GBM in CFA and 
Injected with Anti-ICAM-I and LFA-I mAbs from Day 2 before 
Immunization to Day 14.  The renal abnormalities were strik- 
ingly less in this group than in GBM-immunized rats not 
given anti-ICAM-1 or anti-LFA-1  antibodies (groups II and 
III). At 14 d, mouse IgG (presumably anti-ICAM-1) was found 
on the glomerular endothelium (Fig. 5 g). Thus, it was not 
feasible  to  detect  ICAM-1  in  glomeruli  by  indirect  im- 
munofluorescence. The levels of antibodies to the or3 chain 
of type IV collagen (23.0  _  6.2 U) were slightly lower than 
those in 15 of 16 rats in group II whose antibodies were mea- 
sured (Fig. 3), but the intensity of staining for rat IgG (+ + +) 
and C3 in the GBM was similar to that of group II. Neverthe- 
less, the glomeruli, tubules, and interstitium appeared histo- 
logically  normal  (Fig.  6).  In  particular,  there  was  no 
mononuclear cell infiltration of glomerular tufts. Urinary pro- 
tein excretion (Fig. 1) was also normal. The total PBL count 
was 7,570  _  1,143/mm  3, with 27  _  4% polymorphonu- 
clear and 73  _  4%  mononuclear leukocytes. 
5 wk after immunization, and 3 wk after cessation of in- 
jections of antibodies to ICAM-1 and LFA-1, there was still 
intense staining for rat IgG (+ + +) in the GBM. However, 
levels of circulating antibodies to the or3 chain of type IV 
collagen were lower than those of rats in group II (Fig.  3). 
Mouse IgG was no longer detectable in glomeruli. Antibodies 
to ICAM-1 reacted intensely with the glomerular endothelium 
and with the brush border of proximal tubules. LFA-1 + cells 
were now present in glomeruli and in the interstitium. The 
glomerular and tubulointerstitial abnormalities were strik- 
ingly less than those seen at 5 wk in group II (Fig.  7 a). 
In particular, the formation of crescents was remarkably re- 
duced. Small deposits of fibrinogen/fibrin were found im- 
mediately around some glomeruli, but not in Bowman's space 
(Fig.  7 a, inset), and sclerosis of glomerular tufts was not 
present. Proteinuria (Fig. 1) and serum creatinine levels were 
less than in groups II and III. The PBL counts were normal. 
12 wk after immunization the rats were still  alive. 
670  Antibodies  That Prevent Crescent  Formation in Rat Glomerulonephritis Figure  2.  Glomerular lesions  14 d after immunization of rats with GBM in CFA (group II). (a) Irregular hypercellularity of glomerular tufts is 
seen (H&E;  x 800); (b) cells reactive with ED1 (monocyte/macrophages) are seen in the glomerulus; (c) infiltration of LFA-1  + cells in the glomerulus 
and focally in the interstitium. There is only faint staining for ICAM-1 in the g]omerular capillary walls on day 7 (d), and markedly increased expression 
on day 14 (e); the section in e is contiguous to that in c.  (b-e)  x400. 
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Figure 3.  Circulating antibodies  to the o~3 chain of type IV collagen 
detected by ELISA. The columns represent  the average of the results of 
16 randomly selected rats at 2 wk, and seven at 5 wk in group II, all rats 
at 2 wk, and seven at 5 wk in group IV, and all rats at 5 wk in group 
VL At 2 wk the difference in titers between groups  II and IV was not 
statistically significant. The average titer in rats of group IV was 23.0  • 
6.2 U. One rat in group II had an unusually high rite, of antibodies (350 
U), and all the other 15 rats had relatively low titers  (36.3  •  21.8 U). 
At 5 wk, however, the rite* of antibodies  in group IV was significantly 
lower than in group II (p <0.05).  At 5 wk, the titers  of antibodies  in 
group VI were comparable  to those in group II. 
Group V. Rats Immunized and Injected with Anti-ICAM-! 
and LFA-I mAbs  from Day 2  before Immunization to Day 
35.  On day 14, the kidneys appeared normal in histologic 
sections despite accumulation of  rat IgG in the GBM (+ + +). 
At 5 wk, the histologic and functional changes were strik- 
ingly less severe than those seen in groups II and III, and 
were even less severe than in group IV; in particular  there 
was almost complete absence of crescent formation. By way 
of contrast,  the intensity of staining for IgG in the GBM 
(+ + +) was comparable to that seen in groups  II and III. 
All the rats in group V were alive 20 wk after immunization. 
Group VI. Rats Immunized  with Bovine GBM in CFA and 
Injected with Anti-ICAM-1  and  LFA-1 mAbs from Days 
I4-35.  On day 14, at the start of  injections ofanti-ICAM-1 
and LFA-1 antibodies, renal tissue showed histologic and im- 
munofluorescence findings similar to those in immunized rats 
in groups II and III. At 5 wk, the intensity of staining for 
rat IgG (+ + +) in the GBM and the titers of the antibodies 
to the c~3 chain of  type IV collagen (Fig. 3) were comparable 
to those rats in group II. Nevertheless, the histologic abnor- 
malities in group VI were considerably less severe;  they were, 
however, more severe than in group V. The rats of group 
VI  had  developed  mild  acute,  focal,  glomerulonephritis 
(Fig.  7  b),  but  had only a few small crescents, minimal 
periglomerular deposits of fibrinogen/fibrin (Fig. 7 c), only 
mild proteinuria, and mild increase of serum creatinine levels. 
Discussion 
In the present study, we showed that injections of mAbs 
against ICAM-1 and LFA-1 largely suppressed the develop- 
ment of autoimmune anti-GBM glomerulonephritis in rats, 
when treatment was started shortly before immunization with 
the GBM preparation  and continued for 2 wk or more. Of 
particular  importance,  crescent formation was largely pre- 
vented. In addition, even  when treatment was started shortly 
Figure 4.  Rat of group II 5 wk 
after  immunization  with  GBM. 
Crescentic,  sderosing,  glomerulo- 
nephritis,  and  tubular  atrophy  is 
shown  (H&E,  x350).  The  inset 
(x500) shows deposition of fibrino- 
gen/fibrin in glomerular tufts and 
in a crescent. 
672  Antibodies  That Prevent  Crescent  Formation in Rat Glomerulonephritis Figure  5.  (a-J)  Hndings 5 wk after immunization with GBM (group II). (a) ICAM-1 in the capillary  walls and in the mesangial  matrix ofa glomerulus, 
and (b) in the brush border of the proximal tubules; (c) infiltration of W3/13 + cells (T lymphocytes) in a glomerulus and in the interstitium; (d) 
infiltration of ED1 § cells (monocyte/macrophages)  in and around a glomerulus, and in the interstitium; (e) LFA-1  + cells in a crescent,  and (/) infiltrating 
Bowman's capsule. (g) Deposition of mouse IgG in the glomerular capillaries of a rat of group IV after 16 d of injections with anti-ICAM-1 and 
LFA-1 antibodies. (a-J) xS00; (g)  x150. 
after the onset of disease, at 14 d, progression of glomerular 
lesions  was  markedly reduced. 
Two general types of mechanisms may explain the results. 
The mAbs  may interfere with  the autoimmune  anti-GBM 
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response;  or, treatment may block effector mechanisms,  ei- 
ther by causing lysis of effector leukocytes or by preventing 
the intraglomerular attachment and emigration of leukocytes. 
Experiments with other models have provided evidence that Figure  6.  Photomicrograph 
showing a representative section of 
renal tissue obtained 14 d after im- 
munization  from  a  rat  injected 
with anti-ICAM-1 and LFA-1  anti- 
bodies  (group  IV).  Glomeruli, 
tubules,  and  interstitium  appear 
normal.  H&E;  x300. 
these two types of mechanisms may account for protective 
effects of anti-ICAM-1 and/or anti-LFA-1 antibodies, which 
have been observed in mice with coUagen-induced arthritis 
(23), in mice with cardiac allografts (24), in rats with ad- 
juvant arthritis  (25), in rabbits with Shwartzman-like reac- 
tions  (26) or with lung inflammation induced by phorbol 
ester (27), in nonhuman primates with renal allografts (28), 
and in humans with bone marrow allografts (29). A syner- 
gistic effect was obtained in mice with cardiac allografts by 
simultaneous administration  of anti-ICAM-1  and LFA-1 an- 
tibodies.  Thus,  although the injection  of either antibody 
slightly prolonged the survival of cardiac allografts, the in- 
jection of both antibodies induced permanent and specific 
tolerance of the graft (24). 
Evidence obtained in the present study favors the interpre- 
tation that the principal mechanism by which the mouse anti- 
ICAM-1 and LFA-1 antibodies protected against anti-GBM 
glomerulonephritis  was by interference with attachment and 
emigration of  leukocytes in glomeruli. First, in untreated rats 
there was markedly increased expression of ICAM-1 in glo- 
merular endothelium at days 10-14, associated with infiltra- 
tion of LFA-1  + T lymphocytes and monocyte/macrophages. 
In treated rats, mouse IgG (presumably anti-ICAM-1)  was 
detected transiently on glomerular endothelium, and glomer- 
ular infiltration of  T lymphocytes and monocyte/macrophages 
was reduced or eradicated. Furthermore, 3 wk after discon- 
tinuing injection of anti-ICAM-1 and LFA-1 antibodies (group 
IV), when mouse IgG was no longer detected in glomeruli, 
T  lymphocytes and  monocyte/macrophages were seen in 
glomeruli.  In addition,  the finding that anti-ICAM-1  and 
LFA-1 antibodies given  after onset of disease, on day 14 (group 
VI), reduced the progression of glomerular lesions supports 
the role of interference with effector mechanisms. 
In other models, anti-ICAM-1  and/or LFA-1 antibodies 
have been shown to suppress immune responses, as measured 
either in terms of spedfic T cell responses (23, 25) or anti- 
body production (30, 31). It is possible that in our experi- 
ments reduction in the anti-GBM  response contributed to 
the beneficial  effects  of  the anti-ICAM-1 and LFA-1 antibodies. 
Thus, at 5 wk there was dear-cut reduction in group IV in 
the levels of circulating antibodies to the c~3 chain of type 
IV collagen. Nevertheless, other findings suggest that reduc- 
tion in anti-GBM antibody production played  at most a minor 
role. The levels of anti-GBM antibodies in treated rats (group 
IV) were about the same as those found in 15 of 16 untreated 
rats (group II) at 2 wk. Moreover, in rats treated shortly after 
onset of the renal disease (group VI), anti-GBM antibodies 
were not decreased at 5 wk, although the severity of the renal 
disease at that time was considerably less than in group II. 
In addition,  at both 2 and 5 wk, there was intense linear 
staining for rat IgG in the GBM in treated rats. We have 
not investigated the possibility that rats treated with the anti- 
ICAM-1  and LFA-1 antibodies  have fewer T  lymphocytes 
specifically  reactive with the GBM antigen than in untreated 
immunized rats. 
We failed to find evidence that the injections of the mAbs 
resulted  in  dimination of circulating  LFA-1  +  cells, since 
total  counts  and  percentages  of polymorphonudear and 
mononudear cells were unchanged. 
Our results are clearly different from those of experiments 
in which the administration  of anti-ICAM-1  and LFA-1 an- 
tibodies induced a state of specific tolerance (24, 30, 31). It 
may be that in our model tolerance is difficult or impossible 
to achieve because of the intense stimulation provided by a 
persistent depot of GBM antigen in CFA.  It is of interest 
that in human anti-GBM nephritis, the autoimmune  response 
is generally stir-limited  (32), which suggests that the anti- 
genic stimulus  ceases to operate. 
674  Antibodies That Prevent Crescent Formation in Rat Glomerulonephritis Figure 7.  (a) Section  of kidney  from a rat in group IV at 5 wk, 3 wk after  discontinuation  of the injections  of anti-ICAM-1 and LFA-1 antibodies. 
Slight, irregular hypercellularity  of glomerular tufts is seen, but no crescents. The inset shows moderate deposits of fibrinogen/fibrin  in the 
periglomerular capillaries  of the same rat. (b and c) Sections  from a rat in group VI at 5 wk, that was treated  with anti-ICAM-1  and LFA-1 antibodies 
from days 14 to 35. Glomerular  hypercellularity  is seen but not crescents (b). Periglomerular  deposits of fibrinogen/fibrin  are seen (c). x400. 
Although a major beneficial  effect of anti-ICAM-1 and 
LFA-1 treatment was to reduce glomerular damage, especially 
crescent formation, there was also lessening of tubulointer- 
stitial damage, which is a feature of  experimental and human 
anti-GBM nephritis. In control immunized rats (groups II 
and III) early infiltration oft lymphocytes  and monocyte/mac- 
rophages in glomeruli was associated  with or followed by 
interstitial infiltration of T lymphocytes and monocyte/mac- 
rophages, first around glomeruli and then more extensively 
in the cortical interstitium.  Concomitantly, a marked ex- 
pression of ICAM-1 became evident in the apical part of the 
epithelial cells of the proximal tubules. The abnormal tubular 
expression of ICAM-1, possibly induced by cytokines pro- 
duced within inflamed glomeruli and re.absorbed  by the tubules 
(33), may render this segment of the nephron vulnerable to 
LFA-1 §  effector cells. Leukocytes that cross the tubular base- 
ment membrane and then migrate between tubular ceils or 
leukocytes that enter Bowman's space in the course of cres- 
675  Nishikawa  et al. cent formation may gain access to the apical part of the tubules 
(34). Thus, interference with the ICAM-1/LFA-1 interaction 
may help prevent the development of tubulointerstitial changes, 
which contribute appreciably  to the severity  of anti-GBM 
nephritis. 
In patients with anti-GBM nephritis the prognosis is poor 
unless aggressive  immunosuppressive treatment is initiated 
before development of diffuse circumferential crescents  and 
oliguria (1). The results of our study suggest that early ad- 
ministration of mAbs to ICAM-1 and LFA-1 (possibly in as- 
sociation with "pulses" of intravenous methylprednisolone 
[35] and plasmapheresis  [36])  may constitute a new mode 
of therapy.  In humans, blocking of the ICAM-1/LFA-1 in- 
teraction might be even more effective than in the rat model 
because the anti-GBM response is generally transient and the 
recurrence of the disease is rare  (32). 
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